alexa Membranous nephropathy | Israel | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

  • 11th Global Nephrologists Annual Meeting
    Jun 26-28, 2017, London, UK
  • 2nd Annual Kidney Congress
    Aug 28-30, 2017, Philadelphia, USA
  • 16th European Nephrology Conference
    Oct 02-04, 2017, Barcelona, Spain
  • 16th International Conference on Nephrology
    Nov 02-03, 2017, Atlanta, USA
Read more

Recommended Journals

Relevant Topics

Membranous Nephropathy

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Membranous nephropathy


    Membranous glomerulonephritis 
    (MGN) is a slowly progressive disease of the kidney that leads to changes and inflammation of the structures inside the kidney that help filter wastes and fluids. Membranous Nephropathy (MN) affects men twice as often as women and is more common in adults between the ages of 40 and 70.

  • Membranous nephropathy

    Disease pathophysiology: 

    It develops slowly, over a number of years and people may not realise they have the disorder. Some are identified simply because they are found to have a lot of protein in their urine after a routine test. subepithelial antigen-antibody immune-complex deposition – Diffuse granular IgG and complement deposition along GBM – Different isotypes depending on etiology – Can also have mesangial immune complex deposition (more typical of secondary forms.

     

  • Membranous nephropathy

    Disease statistics:

    We stratified patients into three age categories: <65, 65–70, and ≥71 years old. Clinical characteristics were compared between these three groups using a Wilcoxon rank-sum test or Fisher’s exact test. In approximately 25% of cases the disease is secondary, being greater the percentage in children and elderly patients. 

  • Membranous nephropathy

    Disease treatment: 

    Treating or not idiopathic Membranous Nephropathy (MN) has been a matter of controversy for decades. Some authors emphasize rates of spontaneous remission is considered high and argue against immunosuppressive (IMS) therapy, while others reinforce the high frequency of progression to chronic renal failure and are favorable to IMS. In 1992, Cameron defended the idea that identifying patients at risk to progress to renal failure could give a clue of whom should be treated. 

     

  • Membranous nephropathy

    Major research on disease: 

    Phospholipase A2 Receptor (PLA2R1) Sequence Variants in Idiopathic Membranous Nephropathy. New physiopathological roles for the PLA2R1 receptor in cancer and membranous nephropathy. PLA2R1 is a large transmembrane receptor of 180-kDa that belongs to the Early PLA2R1 physiological roles include the clearance of sPLA2 from the extracellular medium and/or promotion of their actions.

Expert PPTs

Speaker PPTs

  • Hayam I Gad
    Effects of Pravastatin or 12/15 lipoxygenase pathway inhibitors on indices of Diabetic nephropathy in an experimental model of diabetic renal disease
    PPT Version | PDF Version
 

High Impact List of Articles

Conference Proceedings